This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers from Mass General Brigham and collaborating institutions have developed a non-invasive approach to manipulate cardiac tissue activity by using light to stimulate an innovative ink incorporated into bioprinted tissue. Their goal is to develop a technique that can be used to repair the heart. Their findings in preclinical models, published in Science Advances, show the transformative potential of non-invasive therapeutic methods to control electrically active tissues.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts cautioned certain aspects of the study may have inflated its performance.
The FDA has updated the labeling for glatiramer acetate , used for the treatment of multiple sclerosis (MS), to include a boxed warning about the risk of the allergic reaction anaphylaxis. The drug is marketed by Teva Pharmaceuticals as Copaxone and Sandoz sells a generic version of it under the name Glatopa. According to the FDA, cases of anaphylaxis which can be life-threatening in severe cases and if not treated in a timely or effective manner have been reported in patients treated with gla
Research led by the Chiba Cancer Center Research Institute in Japan has discovered a surprising way cancer evades the immune system. It essentially hacks the immune cells, transferring its own faulty mitochondrial DNA (mtDNA) into the T-cells meant to attack it.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Explore the lessons learned from 2024 in pharmacy benefits, including the impact of polypharmacy, biosimilars, and GLP-1 medications, and what to expect for 2025 in this insightful article.
Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.
The vestibular system is a network of organs in the inner ears that detects the motions and position of the head. The brain uses this information, along with inputs from the eyes and joints, to maintain the body's balance.
A new study by researchers at the Department of Molecular Medicine at SDU sheds light on one of the most severe consequences of stroke: damage to the brain's "cables"the so-called nerve fiberswhich leads to permanent impairments. The study, published in The Journal of Pathology, which is based on unique tissue samples from Denmark's Brain Bank located at SDU, may pave the way for new treatments that help the brain repair itself.
Learn how companies are rethinking their digital transformation budgets for 2025 and realigning expectations to effectively leverage technology for business growth.
Although obsessive compulsive disorder (OCD) can be treated, research has shown that people with the disorder tend to have a lower quality of life than neurotypical people. Many struggle to achieve the same levels of education and financial stability as people without the disorder.
Children's Mercy Kansas City has achieved a significant advancement toward the treatment of rare genetic diseases through the use of personalized antisense oligonucleotides (ASOs). This innovative approach has shown promising results in preclinical evaluations, which offers new hope for patients with previously untreatable conditions and validates personalized therapies for patients in only eight weeks, significantly faster and more cost-effective than the industry average.
In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Amanda Salindong, associate director of channel & distribution at Alnylam Pharmaceuticals, describes how she supports her organizations channel strategy.
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission. The team identified that a key cell type in the DLI product and features of the tumor microenvironment in patients both play a role.
Learn more about JP Morgan Week 2025 and gain insight into Fabrizio Chines through an exclusive video interview. Discover valuable information shared during this exciting event.
Artificial Intelligence (AI) could become a radiologist's best friend, with researchers training the technology to accurately diagnose pneumonia, COVID-19 and other lung diseases.
Learn how healthcare professionals (HCPs) can utilise social media advocacy to support the Treat and Reduce Obesity Act. Discover effective strategies and tips for engaging with legislators and promoting awareness of obesity-related initiatives.
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
123 
Let's personalize your content